ClinicalTrials.gg
Not yet recruitingNCT07095478NeoART-CINUpdated Jul 31, 2025

Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer

A Phase 2 interventional study of Artesunate in CIN 2/3, sponsored by Metanoic Health Ltd.. Not yet recruiting at 5 sites in Malaysia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Metanoic Health Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2/3), to investigate if a course of treatment with oral artesunate can reverse pre-cancerous changes in the cervix and prevent the development and progression of invasive cancer. Findings from this study will increase our understanding of the effects of artesunate on CIN2/3 and if confirmatory inform future clinical studies.

Read the detailed description

Cervical cancer is the fourth most common form of cancer in women globally. It is a significant cause of morbidity and mortality, with over half a million new cases and over 300,000 deaths per year despite being preventable and curable if detected early and managed effectively. Low- and middle-income countries (LMICs) are disproportionately affected, with 80% of cases and 90% of cervical cancer-related deaths occurring in low-resource settings. There is an urgent need to develop affordable therapeutics to manage this global oncology burden. For many women, travel costs, time off work, and childcare responsibilities represent significant barriers to engaging with cervical cancer screening, treatment, and follow-up.

The World Health Organization (WHO) cervical cancer elimination strategy has set a target to eliminate cervical cancer as a public health problem (target incidence \<4/100,000 population). To be on track to achieve this by the end of the century, draft targets include: 90% of girls vaccinated against HPV by the age of 15 years; 70% of all women aged 30 to 49 years receiving at least two high-precision screening tests 10 years apart; and 90% of screen-positive women, as well as 90% of women diagnosed with cervical cancer, receiving treatment by 2030. Countries are called to meet the 90-70-90 targets by 2030 in order to progress toward cervical cancer elimination. It is estimated that over 62 million deaths due to cervical cancer could be prevented in the next 100 years through implementation of this strategy alongside HPV vaccination.

While survival rates from colorectal, breast, prostate, cervical, and lung cancer are improving in high-income countries (HICs) due to a combination of early detection and more effective treatments, cancer death rates in LMICs are increasing. This is in part because many lifesaving cancer treatments remain unaffordable in LMICs, where cancer remains a neglected disease. Novel drug development takes an average of 10-15 years to go from bench to clinic at an average cost of USD 1 billion. Repurposing of established drugs for new indications can shorten this pathway substantially and reduce development costs.

In Malaysia, cervical cancer is the fourth leading cause of cancer-related morbidity and mortality among women, with an annual incidence of 1,700 cases reported in 2018. At present, only approximately 25% of women participate in regular cervical screening, and many patients present with advanced disease, with five-year overall survival around 52%. There is an urgent need for effective, safe, and affordable treatments to improve survival.

Artesunate belongs to the artemisinin family of sesquiterpene trioxane anti-malarial agents derived from Artemisia annua L. (Sweet wormwood), which has been used in traditional Chinese medicine for centuries to treat a variety of conditions including fever, inflammation, and haemorrhage. Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria, is listed on the WHO Essential Medicines List, and is available at low cost (approximately USD 1 per daily dose).

Several comprehensive reviews have examined the anticancer effects of artemisinins. Pre-clinical studies in cell lines and animal models have demonstrated broad anticancer activity, including pro-apoptotic, anti-proliferative, anti-angiogenic, and anti-metastatic effects. A Phase I dose-escalation study of artesunate vaginal inserts in biopsy-confirmed cervical intraepithelial neoplasia (CIN) 2/3 in 28 participants demonstrated that treatment was safe and well tolerated, with histologic regression observed in 19 of 28 (67.9%) and HPV viral clearance in 9 of 19 (47.4%) participants. In participants who did not experience histological regression, no viral clearance was observed.

NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in participants with high-grade cervical intraepithelial neoplasia (CIN2/3), with the objective of determining whether a course of oral artesunate can reverse pre-cancerous cervical changes and prevent progression to invasive cancer. Findings from this study will increase scientific understanding of the effects of artesunate on CIN2/3 and may inform future clinical studies.

The primary research objective is to assess the feasibility, safety, and preliminary anti-proliferative activity of oral artesunate in HPV-positive high-grade CIN2/3.

A maximum of 28 participants will be enrolled to receive the study intervention. The primary endpoint is histological regression of CIN2/3, confirmed by colposcopy and biopsy at Day 90. The statistical design tests the null hypothesis that the response rate is 20%, versus the alternative that the response rate is 50%. The significance level is α=0.1, and the power is 90% when the true response rate is 50%. At a significance level of 0.05 and an equivalence margin of 0.15, a sample size of 24 participants is required to achieve 90% power, assuming a historical control response rate of 0.2 and an expected treatment response of 0.5. Accounting for a 20% loss to follow-up, the total sample size is inflated to approximately 28 participants.

Cervical cancer represents significant morbidity and mortality globally, particularly in LMICs. The current standard of care for women with high-grade CIN2/3 includes surgical or ablative treatments. Although these are generally safe, complications such as infection, bleeding, perforation, and cervical stenosis can occur. The most serious late complication is an increased risk of preterm birth and obstetric complications. Even after surgical resection with uninvolved margins, the risk of recurrence may range from 8% to 23%. For many women, barriers such as travel costs, time off work, and childcare continue to impede access to screening, treatment, and follow-up. There is an urgent need to develop safe, effective, and affordable therapeutics that can be delivered at the point of need. An oral treatment that is safe, effective, affordable, and capable of inducing regression of CIN2/3 and HPV clearance would represent a significant advance in the management of this condition.

Trial-specific risks and burdens include additional diagnostic, therapeutic, and monitoring procedures to assess safety, tolerability, and preliminary antiproliferative effects. Participants may not receive direct clinical benefit from participation, but their involvement will contribute to advancing scientific and clinical understanding of artesunate's potential role in treating CIN2/3.

02

Conditions studied

  • CIN 2/3

Keywords

  • CIN
  • HPV
  • drug repurposing
  • Artesunate
  • antimalarial
03

In context

Lead sponsor

Metanoic Health Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 or over
  • proven HPV positive cervical CIN2/3
  • 0-2
  • Adequate full blood count:
  • White Cell Count (WCC) >3.0 x 109 /l;
  • >100 x 109/l;
  • (Hb) >80g/L
  • Adequate renal function:
  • >30ml/min
  • Adequate hepatobiliary function:
  • Total \< 3 x Upper limit normal
  • Female participants of child bearing potential must have a negative pregnancy test \< 72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved precautions for up to 6 weeks after the last dose of study treatment intervention
  • Patient able and willing to provide written, for the study

Exclusion criteria

Exclusion Criteria:

    • to the use of artesunate due to

      • Pregnancy or lactation
      • Weight \< 52 kg
      • History of previous CIN
      • patients
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Artesunate

    200mg oral tablets once daily for 14 days, with 7 days break for 3 cycles.

    Drug: Artesunate

Interventions

  • Patients with HPV positive CIN2/3 will receive 3 cycles of oral artesunate 200mg OD prior to standard of care therapeutic LLETZ. Each 21 day treatment cycle will comprise oral artesunate 200mg OD for 14 days followed by a 7 day treatment break.

06

What researchers measure

Primary outcomes

  1. Histological regression of CIN2/3 on colposcopy and biopsy at Day 90

    Histological regression will be defined as histologic regression to CIN1 or less.

    Time frame: From enrolment to end of trial at Day 90

Secondary outcomes

  1. HPV DNA viral clearance at Day 90.

    Viral clearance will be defined as absence of HPV genotoype (s) detected at baseline.

    Time frame: Measured at the end of the trial at Day 90

  2. Change in Vaginome Composition

    Vaginal microbiota composition will be assessed using gene sequencing of vaginal swab samples collected at Day 1, Day 64, and Day 90. Changes in microbial diversity and relative abundance of dominant bacterial genera (e.g., Lactobacillus, Gardnerella) will be compared across time points. Microbial community structure will be analysed to evaluate shifts associated with the study intervention. Unit of Measure: Relative abundance (%), alpha diversity index, beta diversity distance metrics

    Time frame: At Day 1 , Day 64 of enrolment and at the end of the trial at Day 90

  3. Change in Gut Microbiome Composition Assessed

    Gut microbiota composition will be assessed using gene sequencing of stool samples collected at Day 1, Day 64, and Day 90. Outcomes will include changes in relative abundance of dominant phyla (e.g., Firmicutes, Bacteroidetes), as well as measures of microbial diversity (alpha and beta diversity). Differences in community structure over time will be evaluated in relation to treatment exposure. Unit of Measure: Relative abundance (%), alpha diversity index, beta diversity distance metrics

    Time frame: At Day 1 , Day 64 of enrolment and at the end of the trial at Day 90

  4. Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: Assessment at Day 90 following study intervention

  5. Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires at Baseline

    Quality of life will be assessed using validated, self-administered EQ- 5D-5L health questionnaire. Unit of Measure: Mean scores for each scale/domain of the EQ- 5D-5L questionnaires.

    Time frame: Assessment at Day 1 of study intervention (baseline)

  6. Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires

    Quality of life will be assessed using validated, self-administered EQ- 5D-5L health questionnaire. Unit of Measure: Mean scores for each scale/domain of the EQ- 5D-5L questionnaires.

    Time frame: Assessment at Day 7 of study intervention

  7. Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires

    Quality of life will be assessed using validated, self-administered EQ- 5D-5L health questionnaire. Unit of Measure: Mean scores for each scale/domain of the EQ- 5D-5L questionnaires.

    Time frame: Assessment at Day 14 of study intervention

  8. Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires

    Quality of life will be assessed using validated, self-administered EQ- 5D-5L health questionnaire. Unit of Measure: Mean scores for each scale/domain of the EQ- 5D-5L questionnaires.

    Time frame: Assessment at Day 22 of study intervention

  9. Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires

    Quality of life will be assessed using validated, self-administered EQ- 5D-5L health questionnaire. Unit of Measure: Mean scores for each scale/domain of the EQ- 5D-5L questionnaires.

    Time frame: Assessment at Day 43 of study intervention

  10. Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires

    Quality of life will be assessed using validated, self-administered EQ- 5D-5L health questionnaire. Unit of Measure: Mean scores for each scale/domain of the EQ- 5D-5L questionnaires.

    Time frame: Assessment at Day 64 of study intervention

  11. Patient-Reported Quality of Life (QoL) Assessed by Validated Questionnaires

    Quality of life will be assessed using validated, self-administered EQ- 5D-5L health questionnaire. Unit of Measure: Mean scores for each scale/domain of the EQ- 5D-5L questionnaires.

    Time frame: Assessment at Day 90 of study intervention

  12. Change in Blood Biomarker Levels Associated with Cervical Intraepithelial Neoplasia (CIN 2/3)

    Blood samples will be collected from participants with biopsy-confirmed CIN 2/3 at baseline (Day 1), Day 14, Day 64, and Day 90. Selected biomarkers relevant to HPV-related cervical dysplasia (e.g., pro-inflammatory cytokines such as IL-6, TNF-α, IFN-γ; and HPV-specific antibodies) will be quantified using validated immunoassays. The outcome will report changes in biomarker concentrations over time in relation to histological response. Unit of Measure: Concentration of biomarkers (e.g., pg/mL, IU/mL); fold-change from baseline

    Time frame: Day 1, Day 14, Day 64, and Day 90

07

Study locations

5 sites
08

References and documents

Publications

  • Liu Z, Zhang J, Li S, Jiang J. Artesunate Inhibits Renal Ischemia Reperfusion-Stimulated Lung Inflammation in Rats by Activating HO-1 Pathway. Inflammation. 2018 Feb;41(1):114-121. doi: 10.1007/s10753-017-0669-3. PubMed 28921399 ↗
  • Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci. 2008 Oct;29(10):520-7. doi: 10.1016/j.tips.2008.07.004. Epub 2008 Aug 25. PubMed 18752857 ↗
  • Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair (Amst). 2019 Nov;83:102673. doi: 10.1016/j.dnarep.2019.102673. Epub 2019 Jul 25. PubMed 31387777 ↗
  • Jansen FH, Adoubi I, J C KC, DE Cnodder T, Jansen N, Tschulakow A, Efferth T. First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. Anticancer Res. 2011 Dec;31(12):4417-22. PubMed 22199309 ↗
  • Ho WE, Peh HY, Chan TK, Wong WS. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther. 2014 Apr;142(1):126-39. doi: 10.1016/j.pharmthera.2013.12.001. Epub 2013 Dec 6. PubMed 24316259 ↗
  • Heinonen A, Gissler M, Riska A, Paavonen J, Tapper AM, Jakobsson M. Loop electrosurgical excision procedure and the risk for preterm delivery. Obstet Gynecol. 2013 May;121(5):1063-1068. doi: 10.1097/AOG.0b013e31828caa31. PubMed 23635744 ↗
  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013. PubMed 21376230 ↗
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. PubMed 30207593 ↗
  • Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2018 Mar;81(3):587-596. doi: 10.1007/s00280-018-3533-8. Epub 2018 Feb 1. PubMed 29392450 ↗
  • Augustin Y, Staines HM, Krishna S. Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing. Pharmacol Ther. 2020 Dec;216:107706. doi: 10.1016/j.pharmthera.2020.107706. Epub 2020 Oct 16. PubMed 33075360 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form, Clinical study report

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Jun 2027, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 31, 2025
StartEst.
Aug 1, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07095478
Lead sponsor
Metanoic Health Ltd.
Collaborators
Clinical Research Malaysia
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jul 31, 2025

Study contacts

Professor Sanjeev Krishna, FRCP,ScD
Contact
skrishna@cadt.org.uk
+442087250446
Dr Yolanda Augustin
Contact
yaugustin@cadt.org.uk
Professor Sanjeev Krishna, FRCP, ScD
study chair · Centre of Diagnostics and Therapeutics
Dr Yolanda Augustin
principal investigator · Centre of Diagnostics and Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Artesunate

Start the discussion